Clinical Trial Update: Alemtuzumab to Treat Severe Aplastic Anemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alemtuzumab for severe aplastic anemia (refractory/relapse) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia, Relapse | Phase 2 | Status: COMPLETED | Results posted: 2019-08-02